A respected RNAi therapeutics firm.

, a respected RNAi therapeutics firm, announced today that it will present brand-new data from its ALN-TTR plan at the VIIIth International Symposium on Familial Amyloidotic Polyneuropathy becoming held in Kumamoto, From November 20-22 Japan, 2011. This consists of data from its blinded, randomized, placebo-controlled, single dose escalation Phase I clinical trial of ALN-TTR01 in patients with transthyretin -mediated amyloidosis . Related StoriesExpanded use for IntelliCap with further CE Tag for aspiration of fluidsLiposomal sizing and the Coulter principle: an interview with Professor Melvin E. KlegermanPresentations from Alnylam researchers at the conference include: a demonstration titled Quantitation of wild-type, V30M, and V122I serum TTR protein by an LC-MS/MS method in humans with amyloidogenic mutant TTR variants,on Sunday in the Oral presentation 2 session being held, 20 from 12:00 p November.m.Ondansetron Exposure We used info from the National Prescription Registry to identify prescriptions for ondansetron dispensed to women in the cohort. No woman had used any various other 5-hydroxytryptamine type 3 receptor antagonist. We described specific exposure time windows for the respective analyses: the first trimester for just about any main birth defect, any moment before 37 finished weeks for preterm delivery, any right period during being pregnant for analyses including birth pounds, week 7 through week 22 for spontaneous abortion, and week 7 until birth for stillbirth. The timing of exposure was described by the time the prescription was loaded.